Publicacións en colaboración con investigadores/as de Leiden University Medical Center (20)

2022

  1. After JAK inhibitor failure: To cycle or to switch, that is the question - Data from the JAK-pot collaboration of registries

    Annals of the Rheumatic Diseases, Vol. 82, Núm. 2, pp. 175-181

2019

  1. Evaluation of 12 GWAS-drawn SNPs as biomarkers of rheumatoid arthritis response to TNF inhibitors. A potential SNP association with response to etanercept

    PLoS ONE, Vol. 14, Núm. 2

2018

  1. Validation study of genetic biomarkers of response to TNF inhibitors in rheumatoid arthritis

    PLoS ONE, Vol. 13, Núm. 5

2017

  1. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update

    Annals of the Rheumatic Diseases, Vol. 76, Núm. 6, pp. 960-977

2016

  1. Evidence for treating rheumatoid arthritis to target: Results of a systematic literature search update

    Annals of the Rheumatic Diseases, Vol. 75, Núm. 1, pp. 16-22

  2. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force

    Annals of the Rheumatic Diseases, Vol. 75, Núm. 1, pp. 3-15

2012

  1. Golimumab in psoriatic arthritis: One-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial

    Arthritis and Rheumatism, Vol. 64, Núm. 8, pp. 2504-2517

  2. Treating rheumatoid arthritis to target: Recommendations of an international task force

    Revmatologiia (Bulgaria), Vol. 20, Núm. 2, pp. 5-16

2011

  1. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials

    Annals of the Rheumatic Diseases, Vol. 70, Núm. 3, pp. 404-413

  2. American college of rheumatology/European league against rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials

    Arthritis and Rheumatism, Vol. 63, Núm. 3, pp. 573-586

  3. Insights into the genetic architecture of osteoarthritis from stage 1 of the arcOGEN study

    Annals of the Rheumatic Diseases, Vol. 70, Núm. 5, pp. 864-867

  4. Treating rheumatoid arthritis to target: Multinational recommendations assessment questionnaire

    Annals of the Rheumatic Diseases, Vol. 70, Núm. 11, pp. 1999-2002

2010

  1. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

    Annals of the Rheumatic Diseases, Vol. 69, Núm. 6, pp. 964-975

  2. Treating rheumatoid arthritis to target: Recommendations of an international task force

    Annals of the Rheumatic Diseases, Vol. 69, Núm. 4, pp. 631-637

2009

  1. Association of a nsSNP in ADAMTS14 to some osteoarthritis phenotypes

    Osteoarthritis and Cartilage, Vol. 17, Núm. 3, pp. 321-327

  2. Large replication study and meta-analyses of DVWA as an osteoarthritis susceptibility locus in European and Asian populations

    Human Molecular Genetics, Vol. 18, Núm. 8, pp. 1518-1523

  3. Large-scale analysis of association between GDF5 and FRZB variants and osteoarthritis of the hip, knee, and hand

    Arthritis and Rheumatism, Vol. 60, Núm. 6, pp. 1710-1721

  4. Testing the druggable endothelial differentiation gene 2 knee osteoarthritis genetic factor for replication in a wide range of sample collections

    Annals of the Rheumatic Diseases, Vol. 68, Núm. 6, pp. 1017-1021

2008

  1. Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations

    Arthritis Care and Research, Vol. 59, Núm. 10, pp. 1371-1377

2007

  1. Consensus statement on the use of rituximab in patients with rheumatoid arthritis

    Annals of the Rheumatic Diseases, Vol. 66, Núm. 2, pp. 143-150